Ketamine analogue Methoxetamine and related deaths in the UK during 2011-2012: descriptive and clinical characteristics of national programme on Substance Abuse Deaths (np-SAD) cases

First published: 29/03/2019 | Last updated: May 20th, 2019

{alt_text}

Mrs Christine Goodair

Programmes Manager ( Substance Misuse) Population Health Research Institute, St George’s, University of London

Since 2007  I have been at St. George’s working on a range of substance misuse projects. My current programmes of work are Substance Misuse in the Undergraduate Medical Curriculum, EU- Madness, a project monitoring the health harms of novel psychoactive substances, the National Programme on Drug Related Deaths and helping with the St George’s heritage/archives programme.

Previously, I worked for over 20 years in special libraries and information services. My last information role was at DrugScope as manager of their information services and website, including working on two European projects on addictions.

Although methoxetamine has been banned since April 2012, its misuse appears to be increasing. Several cases of acute toxicity reported hyper activation symptoms. This poster discusses the largest known case series of methoxetamine fatalities in the UK.

Resources



Download the presentation

Download the full presentation here

Mrs Christine Goodair


 

Covid-19

As an organisation, we continue to function during the developing pandemic.

We are following all government and Charity Commission guidance in respect of staff and reporting issues.

Our funding schemes remain open and we are continuing to programme our conferences planned for November 2020.